$MRAM

FINCH LAWRENCE G sold $1.4M of MRAM (indirect holdings)

FINCH LAWRENCE G sold 41,961 indirectly-held shares of EVERSPIN TECHNOLOGIES INC. (MRAM) at $34.29 ($1.44M total) on 2026-05-11.

Original reporting
SEC EDGAR · FINCH LAWRENCE G
Published Jun 2, 2026, 9:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MRAM
Neutral
medium confidence
Mentioned
$MRAM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRAMNeutralLow
01

Why it matters

The disclosure may slightly pressure near-term sentiment, but it does not change the company’s fundamentals or provide new guidance/contract/clinical/regulatory information.

02

Market read

A single insider sale disclosed after the fact (May 11 sale, filed June 2) with no accompanying corporate catalyst.

03

What to watch

The sale is indirect and not tied to a stated 10b5-1 plan; without context on prior holdings, it’s hard to infer conviction or timing.

Relevance 6/10Novelty 6/10Timing: Filed June 2, covering sale dated May 11

Background

SEC Form 4 insider transaction for Everspin Technologies (MRAM) showing an open-market sale by a director; no 10b5-1 plan is indicated.

Company-level read

Ticker impact

$MRAMNeutralMedium confidence
Context

Everspin Technologies director Lawrence Finch sold 41,961 shares in an open-market transaction totaling about $1.44M, reducing holdings to zero.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely limited and short-lived.

Evidence & confidence

This is a routine insider sale (no 10b5-1 plan cited) with no accompanying operational or financial update, so it typically has limited incremental information value.

Market effects

Minor read-through for MRAM/heat-assisted magnetic recording (HAMR) sentiment, but no sector-wide catalyst is introduced.

None indicated; US-listed microcap/SMID insider activity only.

None indicated; transaction is company-specific and not tied to global demand or regulation.

Counterpoint

Director selling could be driven by diversification/taxes rather than negative expectations, especially since the filing provides no rationale.

Key entities

  • Everspin Technologies Inc.

    Subject of the Form 4 insider sale; director Lawrence Finch sold 41,961 shares.

  • FINCH LAWRENCE G

    Director who executed the open-market sale; holdings after transaction reported as 0 shares.

Related articles

$MRAMMed

EVERSPIN TECHNOLOGIES INC. (MRAM): Results of Operations and Financial Condition

EVERSPIN TECHNOLOGIES INC. (MRAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mram-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 Everspin Reports Unaudited Second Quarter 2026 Financial Results Chandler, AZ, August 5, 2026 —Everspin Technologies, Inc. (NASDAQ: MRAM), the world’s leading developer and manufacturer of Magnetoresistive Random Ac

$MRAMMed

Everspin stock surges 14% on MaxLinear AI server partnership

Everspin Technologies (NASDAQ:MRAM) shares rose 14% and MaxLinear (NYSE:MXL) gained 9% after both firms announced an MOU to evaluate next-generation memory architectures for AI servers. The plan combines Everspin’s persistent low-latency MRAM with MaxLinear’s storage compression, encryption and acceleration platform, targeting data-intensive workloads and market development for cloud and enterprise customers.

$NVDAMedAI 9/10

MarketBeat Week in Review – 05/18 - 05/22

Stocks rose into the week’s close, with NVIDIA (NVDA) results and forward guidance cited as evidence of tangible demand for AI infrastructure. Retail stocks showed a mixed consumer backdrop amid inflation concerns. U.S. markets were closed Monday for Memorial Day. The review also highlighted items including SpaceX’s public S-1 filing and a Phase 2 Alzheimer’s trial miss at Biogen (BIIB).